Loomis, Sayles & Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$11M Buy
43,544
+16,941
+64% +$3.64M 0.01% 373
2026
Q1
$5.79M Sell
26,603
-1,535
-5% -$341K 0.01% 402
2025
Q4
$6.43M Sell
28,138
-10,769
-28% -$2.45M 0.01% 404
2025
Q3
$9.01M Sell
38,907
-15,088
-28% -$3.07M 0.01% 372
2025
Q2
$10M Buy
53,995
+18,866
+54% +$3.51M 0.01% 380
2025
Q1
$7.36M Sell
35,129
-44,285
-56% -$8.61M 0.01% 392
2024
Q4
$14.1M Buy
79,414
+824
+1% +$151K 0.02% 316
2024
Q3
$15.5M Sell
78,590
-136,317
-63% -$25.4M 0.02% 299
2024
Q2
$36.9M Buy
214,907
+44,821
+26% +$7.42M 0.05% 163
2024
Q1
$31M Sell
170,086
-106,412
-38% -$18.3M 0.04% 195
2023
Q4
$42.8M Buy
276,498
+19,285
+7% +$2.81M 0.07% 141
2023
Q3
$38.3M Buy
257,213
+211,591
+464% +$31.1M 0.07% 146
2023
Q2
$6.15M Sell
45,622
-8,521
-16% -$1.25M 0.01% 381
2023
Q1
$8.63M Sell
54,143
-1,075
-2% -$164K 0.02% 346
2022
Q4
$8.92M Sell
55,218
-1,692
-3% -$259K 0.02% 328
2022
Q3
$7.64M Sell
56,910
-134,496
-70% -$19.3M 0.02% 334
2022
Q2
$29.3M Sell
191,406
-110,700
-37% -$16.9M 0.05% 173
2022
Q1
$49M Sell
302,106
-39,231
-11% -$5.7M 0.07% 131
2021
Q4
$46.2M Buy
341,337
+340,755
+58,549% +$40.3M 0.06% 163
2021
Q3
$63K Hold
582
﹤0.01% 583
2021
Q2
$66K Buy
582
+123
+27% +$13.9K ﹤0.01% 580
2021
Q1
$50K Buy
459
+89
+24% +$9.52K ﹤0.01% 565
2020
Q4
$40K Sell
370
-10,932
-97% -$1.05M ﹤0.01% 556
2020
Q3
$989K Sell
11,302
-257
-2% -$24.2K ﹤0.01% 454
2020
Q2
$1.14M Sell
11,559
-2,446
-17% -$215K ﹤0.01% 438
2020
Q1
$1.07M Sell
14,005
-13,371
-49% -$1.14M ﹤0.01% 445
2019
Q4
$2.42M Sell
27,376
-29,328
-52% -$2.43M ﹤0.01% 430
2019
Q3
$4.29M Sell
56,704
-2,242
-4% -$154K 0.01% 410
2019
Q2
$4.29M Sell
58,946
-5,699
-9% -$448K 0.01% 433
2019
Q1
$5.21M Buy
64,645
+10,096
+19% +$826K 0.01% 422
2018
Q4
$5.03M Buy
54,549
+50,378
+1,208% +$4.43M 0.01% 417
2018
Q3
$394K Sell
4,171
-3,234
-44% -$307K ﹤0.01% 573
2018
Q2
$686K Buy
7,405
+1
+0% +$98 ﹤0.01% 562
2018
Q1
$701K Sell
7,404
-3,684
-33% -$405K ﹤0.01% 577
2017
Q4
$1.07M Sell
11,088
-5,122
-32% -$483K ﹤0.01% 563
2017
Q3
$1.44M Sell
16,210
-6,473
-29% -$493K ﹤0.01% 554
2017
Q2
$1.65M Sell
22,683
-153
-0.7% -$10.3K ﹤0.01% 549
2017
Q1
$1.49M Buy
22,836
+2,488
+12% +$156K ﹤0.01% 558
2016
Q4
$1.27M Sell
20,348
-564,063
-97% -$34.4M ﹤0.01% 583
2016
Q3
$36.9M Sell
584,411
-186,107
-24% -$12M 0.09% 128
2016
Q2
$47.7M Sell
770,518
-124,779
-14% -$7.6M 0.13% 99
2016
Q1
$51.1M Buy
895,297
+14,376
+2% +$801K 0.15% 103
2015
Q4
$52.2M Buy
880,921
+165,647
+23% +$9.54M 0.15% 98
2015
Q3
$38.9M Buy
715,274
+707,967
+9,689% +$46.1M 0.12% 138
2015
Q2
$491K Sell
7,307
-2,538
-26% -$166K ﹤0.01% 612
2015
Q1
$576K Sell
9,845
-1,865
-16% -$113K ﹤0.01% 636
2014
Q4
$766K Sell
11,710
-30,962
-73% -$1.95M ﹤0.01% 582
2014
Q3
$2.46M Sell
42,672
-445
-1% -$24.7K 0.01% 562
2014
Q2
$2.43M Sell
43,117
-797
-2% -$41.8K 0.01% 578
2014
Q1
$2.26M Buy
43,914
+1,137
+3% +$57.5K 0.01% 567
2013
Q4
$2.26M Sell
42,777
-367,234
-90% -$18M 0.01% 597
2013
Q3
$18.3M Sell
410,011
-70,985
-15% -$3.15M 0.06% 358
2013
Q2
$19.9K Buy
+480,996
New +$21M 0.07% 302

Other funds holding ABBV

Loomis, Sayles & Company's ABBV Position: Q2 2026 in Review

Loomis, Sayles & Company increased its AbbVie (ABBV) stake by 64% in Q2 2026, buying an estimated $3.64M and bringing the position to 43,544 shares worth $11M. The position accounts for 0.01% of the portfolio, ranked #373.

Loomis, Sayles & Company first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $52.2M in Q4 2015. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Loomis, Sayles & Company held 43,544 shares of AbbVie worth $11M as of Q2 2026.
  • Loomis, Sayles & Company bought 16,941 AbbVie shares in Q2 2026, an estimated $3.64M.
  • AbbVie made up 0.01% of Loomis, Sayles & Company's portfolio in Q2 2026, its #373 holding.
  • Loomis, Sayles & Company first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Loomis, Sayles & Company's AbbVie position peaked at $52.2M in Q4 2015.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Loomis, Sayles & Company's 13F filing for Q2 2026, filed 14 Aug 2026.